Skip to main content

Table 1 PI3K, AKT, and mTOR inhibitors selected for preclinical and clinical development(main PI3K/AKT/mTOR inhibitors in clinical trials) [73,74,75,76,77,78,79,80,81]

From: RETRACTED ARTICLE: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours

Inhibitor Compound or drug Targets Tumor types currently under investigation
PI3K LY294002 Pan-class I PI3K Advanced solid tumors
Buparlisib (BKM120) Pan-class I PI3K Advanced solid tumors
SAR245408 (XL-147) Pan-class I PI3K Advanced solid tumors
Sonolisib (PX-866) P110-Delta, gamma Phase II and III trials in NHL and CLL are underway, both alone and in combination with hantiCD20 antibodies
Pictilisib (GDC-0941) P110-alpha, Delta Added alpha specificity may provide benefit in MCLandsome others versus delta-only inhibitors
Taselisib (GDC-0032) P110-alpha, Delta Advanced solid tumors and metastatic breast cancer (ERþ)
AKT Pirifosine AKT Advanced solid tumors, multiple myeloma
Palomid529(P529) AKT Advanced solid tumors, breast cancer, cervical cancer, endometrial cancer, leukemias, melanoma, multiple myeloma
GSK2141795 AKT Advanced solid tumors, breast cancer, cervical cancer, endometrial cancer, leukemias, melanoma, multiple myeloma
MK-2206 AKT Advanced solid tumors, breast cancer, colorectal cancer, endometrial cancer, head & neck cancer, lung cancer, lymphomas, pancreatic cancer, prostate cancer
mTOR Everolimus(RAD001) mTORC1 Approved for the treatment of renal cell carcinoma, subependymal giant cell astrocytoma associated with tuberous sclerosis, pancreatic neuroendocrine tumors, and ERþ breast cancer
Temsirolimus mTORC1 Approved for the treatment of renal cell carcinoma
Rapamycin mTORC1 Advanced solid tumors, multiple myeloma
Dual NVP-BEZ235 (BEZ-235) P110, mTORC1/2 Advanced solid tumors, multiple myeloma
SAR245409(XL765) PI3K/mTOR Advanced solid tumors, CLL, indolent non-Hodgkin lymphoma, mantle cell lymphoma, ovarian cancer
GDC-0980 PI3K/mTOR Solid cancers, non-Hodgkin lymphoma, breast cancer, prostate cancer